Onsolis is owned by Bdsi.
Onsolis contains Fentanyl Citrate.
Onsolis has a total of 1 drug patent out of which 0 drug patents have expired.
Onsolis was authorised for market use on 16 July, 2009.
Onsolis is available in film;buccal dosage forms.
Onsolis can be used as management of breakthrough pain in patients with cancer.
The generics of Onsolis are possible to be released after 23 July, 2027.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9597288||BDSI||Transmucosal delivery devices with enhanced uptake|| |
(4 years from now)
Market Authorisation Date: 16 July, 2009
Treatment: Management of breakthrough pain in patients with cancer
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic